Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Kaiser, GM; Sotiropoulos, GC; Jauch, KW; Löhe, F; Hirner, A; Kalff, JC; Königsrainer, A; Steurer, W; Senninger, N; Brockmann, JG; Schlitt, HJ; Zülke, C; Büchler, MW; Schemmer, P; Settmacher, U; Hauss, J; Lippert, H; Hopt, UT; Otto, G; Heiss, MM; Bechstein, WO; Timm, S; Klar, E; Hölscher, AH; Rogiers, X; Stangl, M; Hohenberger, W; Müller, V; Molmenti, EP; Fouzas, I; Erhard, J; Malagó, M; Paul, A; Broelsch, CE; Lang, H.
Liver transplantation for hilar cholangiocarcinoma: a German survey.
Transplant Proc. 2008; 40(9):3191-3193
Doi: 10.1016/j.transproceed.2008.08.039
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Schemmer Peter
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The present study reports a German survey addressing outcomes in nonselected historical series of liver transplantation (OLT) for hilar cholangiocarcinoma (HL). We sent to all 25 German transplant centers performing OLT a survey that addressed (1) the number of OLTs for HL and the period during which they were performed; (2) the incidence of HL diagnosed prior to OLT/rate of incidental HL (for example, in primary sclerosing cholangitis); (3) tumor stages according to Union Internationale Centre le Cancer; (4) patient survival; and (5) tumor recurrence rate. Eighty percent of centers responded, reporting 47 patients who were transplanted for HL. Tumors were classified as pT2 (25%), pT3 (73%), or pT4 (2%). HL was diagnosed incidentally in 10% of cases. A primary diagnosis of PSC was observed in 16% of patients. Overall median survival was 35.5 months. When in-hospital mortality (n = 12) was excluded, the median survival was 45.4 months, corresponding to 3- and 5-year survival rates of 42% and 31%, versus 31% and 22% when in-hospital mortality was included. HL recurred in 34% of cases. Three- and 5-year survivals for the 15 patients transplanted since 1998 was 57% and 48%, respectively. Median survival ranged from 20 to 42 months based on the time period (P = .014). The acceptable overall survival, the improved results after careful patient selection since 1998, and the encouraging outcomes from recent studies all suggest that OLT may be a potential treatment for selected cases of HL. Prospective multicenter randomized studies with strict selection criteria and multimodal treatments seem necessary.
- Find related publications in this database (using NLM MeSH Indexing)
- Bile Duct Neoplasms - surgery
- Bile Ducts, Intrahepatic - surgery
- Cholangiocarcinoma - surgery
- Cholangiocarcinoma -
- Hospital Mortality -
- Humans -
- Liver Transplantation - mortality
- Liver Transplantation - physiology
- Retrospective Studies -
- Survival Rate -
- Survivors -
- Time Factors -